Showing 3711-3720 of 8741 results for "".
- Is CBG the Next CBD for Skincare?https://practicaldermatology.com/news/is-cbg-the-next-cbd-for-skincare/2461042/Cannabigerol (CBG) shows antioxidant, anti-inflammatory, and skin health-boosting activity in lab assays and provides similar benefits when applied topically to human skin, according to new research. In a single-blind c
- The National Eczema Association and Pediatric Dermatology Research Alliance Receive Collaborative Engagement Award from PCORIhttps://practicaldermatology.com/news/the-national-eczema-association-and-pediatric-dermatology-research-alliance-receive-collaborative-engagement-award-from-pcori/2461041/The
- Lubriderm Launches Skin Scholarship with the National Hispanic Health Foundationhttps://practicaldermatology.com/news/lubriderm-launches-skin-scholarship-with-the-national-hispanic-health-foundation/2461030/Lubriderm is partnering with the
- Case Study Highlights Possible Role for Minimal Dose Radiotherapy in Severe Acne Keloidalis Nuchaehttps://practicaldermatology.com/news/case-study-highlights-possible-role-for-minimal-dose-radiotherapy-in-severe-acne-keloidalis-nuchae/2461021/Minimal dose radiotherapy may offer new hope for severe acne keloidalis nuchae (AKN), according to research in the Journal of the American Academy of Dermatology Case Reports. The study found t
- FDA Accepts Arcutis Biotherapeutics’ NDA for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasishttps://practicaldermatology.com/news/fda-accepts-arcutis-biotherapeutics-nda-for-roflumilast-cream-for-adults-and-adolescents-with-plaque-psoriasis/2461018/The FDA accepted Arcutis Biotherapeutics’ new drug application (NDA) for roflumilast cream for the treatment of psoriasis in adults and adolescents. The FDA assigned the application a Prescription Drug User Fee Act (PDUFA) target action date of July 29, 2022. “With the FDA c
- Tremfya Five-Year Data Show No New Safety Signalshttps://practicaldermatology.com/news/tremfya-five-year-data-show-no-new-safety-signs/2461016/New data published in the
- Rinvoq Scores FDA Nod for Active Psoriatic Arthritishttps://practicaldermatology.com/news/rinvoq-scores-us-fda-nod-for-active-psoriatic-arthritis/2461012/The U.S. Food and Drug Administration (FDA) has approved RINVOQ (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. "The efficacy
- FDA Accepts NDA for Boehringer Ingelheim’s Spesolimab for GPPhttps://practicaldermatology.com/news/fda-accepts-nda-for-boehringer-ingelheims-spesolimab-for-gpp/2461010/FDA has accepted a Biologics License Application (BLA) and granted Priority Review for Boehringer Ingelheim’s spesolimab for the treatment of generalized pustular psoriasis (GPP) flares. The FDA has granted spesolimab Orphan Drug Designation for the treatment of GPP, and Bre
- NPF Launches Multimedia Resource Center for Health Care Providers Caring for Individuals with Psoriatic Diseasehttps://practicaldermatology.com/news/npf-launches-multimedia-resource-center-for-health-care-providers-caring-for-individuals-with-psoriatic-disease/2461008/The National Psoriasis Foundation (NPF) is committed to offering innovative ways for health care providers (HCPs) to stay up-to-date on the latest news and research related to psoriatic disease. As part of its five-year strategic plan to improve health outcomes for all living with the disease, in
- FDA Approves Higher Dilution in New Sculptra Labelhttps://practicaldermatology.com/news/fda-approves-higher-dilution-in-new-sculptra-label/2461007/A new FDA-approved label for Sculptra® (injectable poly-L-lactic acid (PLLA)) from Galderma includes higher dilution, the addition of immediate use reconstitution, new injection techniques, and the optional addition of lidocaine. Sculptra is the first and only FDA-approved PLLA facial in